In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through ...
Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Learn more about HIMS stock here.
Stocktwits on MSN
Hims & Hers enters 2026 on solid ground — stock rises even after Novo Nordisk leaves it off Wegovy partner list
Hims shares logged their best session in a month and added after-hours gains. ・Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims. ・Hims continues to broaden its platform ...
It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 15.1% in that time frame, underperforming the S&P 500. Will the recent negative ...
Hims & Hers Health, Inc. faces short-term pressure after missing Novo’s partner list, but lab testing boosts long-term growth ...
One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong ...
The Manual on MSN
Why your weight loss plans keep failing (and how Hims fixes that)
This post is brought to you in paid partnership with Hims. We’re one week into the new year. By now, the initial burst of ...
Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a consumer-first, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback